AdvanCell valuation, funding and investors
AdvanCell works in radiopharmaceutical development and manufacturing, based in Sydney, Australia. Founded in 2019, it has about 101 employees.
- Last round
- Series D · $315M · Jul 2026
- Valuation at last round
- $2.86B · implied
- Headcount
- 101 · growing
- Grade
- B
- Founded
- 2019
AdvanCell valuation today
VCMC values AdvanCell at $3.1B today, with a range of $2.1B to $5.4B and a grade of B. The valuation starts from its last funding round, a Series D round in Jul 2026.
Valuation by date (98 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2019 | $4.92M | $1.79M – $13.5M | $6.08M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $5.05M | $1.84M – $13.9M | $6.13M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $5.17M | $1.88M – $14.2M | $6.18M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $5.31M | $1.93M – $14.6M | $6.24M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $5.45M | $1.99M – $15.0M | $6.29M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $5.60M | $2.04M – $15.4M | $6.35M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $5.75M | $2.09M – $15.8M | $6.41M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $5.81M | $2.11M – $16.0M | $6.47M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $5.86M | $2.13M – $16.1M | $6.53M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $5.91M | $2.15M – $16.2M | $6.58M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $5.97M | $2.17M – $16.4M | $6.65M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $6.02M | $2.19M – $16.5M | $6.70M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $6.08M | $2.21M – $16.7M | $6.77M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $6.13M | $2.23M – $16.8M | $6.83M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $6.18M | $2.25M – $17.0M | $6.89M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $6.24M | $2.27M – $17.1M | $6.95M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $6.30M | $2.29M – $17.3M | $7.01M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $6.35M | $2.31M – $17.5M | $7.08M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $6.41M | $2.33M – $17.6M | $7.14M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $6.47M | $2.36M – $17.8M | $7.20M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $6.53M | $2.38M – $17.9M | $7.27M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $6.59M | $2.40M – $18.1M | $7.34M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $6.65M | $2.42M – $18.3M | $7.40M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $6.71M | $2.44M – $18.4M | $7.47M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $6.77M | $2.46M – $18.6M | $7.54M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $6.83M | $2.49M – $18.8M | $7.59M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $6.89M | $2.51M – $18.9M | $7.64M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $6.95M | $2.53M – $19.1M | $7.70M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $7.01M | $2.55M – $19.3M | $7.76M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $7.07M | $2.58M – $19.4M | $7.82M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $7.14M | $2.60M – $19.6M | $7.87M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $7.20M | $2.62M – $19.8M | $7.93M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $7.27M | $2.65M – $20.0M | $7.99M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $7.33M | $2.67M – $20.1M | $8.05M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $7.40M | $2.69M – $20.3M | $8.11M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $7.47M | $2.72M – $20.5M | $8.17M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $7.54M | $2.74M – $20.7M | $8.23M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $7.59M | $2.76M – $20.9M | $8.29M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $6.69M | $2.44M – $18.4M | $7.31M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Apr 2022 | $6.74M | $2.45M – $18.5M | $7.36M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 May 2022 | $6.79M | $2.47M – $18.7M | $7.42M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Jun 2022 | $6.84M | $2.49M – $18.8M | $7.47M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Jul 2022 | $6.89M | $2.51M – $18.9M | $7.53M (+9%) | before first round | 7 | unknown | D | 0% |
| 1 Aug 2022 | $6.94M | $2.53M – $19.1M | $7.58M (+9%) | before first round | 7 | unknown | D | 0% |
| 25 Aug 2022 | $77.2M | $50.7M – $176M | $116M (+50%) | after a round | 7 | unknown | C | 0% |
| 1 Sep 2022 | $77.8M | $50.7M – $176M | $116M (+49%) | after a round | 7 | unknown | C | 0% |
| 1 Oct 2022 | $80.5M | $50.7M – $176M | $116M (+44%) | after a round | 7 | unknown | C | 0% |
| 1 Nov 2022 | $83.3M | $50.7M – $176M | $116M (+39%) | after a round | 7 | unknown | C | 0% |
| 1 Dec 2022 | $86.1M | $50.7M – $176M | $116M (+34%) | after a round | 7 | unknown | C | 0% |
| 1 Jan 2023 | $89.1M | $50.7M – $176M | $116M (+30%) | after a round | 15 | growing | C | 0% |
| 1 Feb 2023 | $92.3M | $50.7M – $176M | $116M (+25%) | after a round | 15 | growing | C | 0% |
| 1 Mar 2023 | $95.2M | $50.7M – $176M | $116M (+22%) | after a round | 15 | growing | C | 0% |
| 1 Apr 2023 | $98.5M | $50.7M – $176M | $116M (+17%) | after a round | 15 | growing | C | 0% |
| 1 May 2023 | $102M | $50.7M – $176M | $116M (+14%) | after a round | 15 | growing | C | 0% |
| 1 Jun 2023 | $105M | $50.7M – $176M | $116M (+10%) | after a round | 15 | growing | C | 0% |
| 1 Jul 2023 | $109M | $50.7M – $176M | $116M (+6%) | after a round | 15 | growing | C | 0% |
| 1 Aug 2023 | $113M | $50.7M – $176M | $116M (+3%) | after a round | 15 | growing | C | 0% |
| 1 Sep 2023 | $116M | $50.8M – $176M | $116M (0%) | after a round | 15 | growing | C | 0% |
| 1 Oct 2023 | $127M | $56.5M – $194M | $127M (0%) | after a round | 23 | growing | C | 0% |
| 1 Nov 2023 | $127M | $57.2M – $194M | $127M (0%) | after a round | 23 | growing | C | 0% |
| 1 Dec 2023 | $127M | $57.9M – $194M | $127M (0%) | after a round | 23 | growing | C | 0% |
| 1 Jan 2024 | $127M | $58.6M – $194M | $127M (0%) | after a round | 23 | growing | B | 0% |
| 1 Feb 2024 | $127M | $59.3M – $194M | $127M (0%) | after a round | 23 | growing | B | 0% |
| 1 Mar 2024 | $129M | $61.1M – $197M | $129M (0%) | after a round | 25 | growing | B | 0% |
| 1 Apr 2024 | $129M | $61.8M – $197M | $129M (0%) | after a round | 25 | growing | B | 0% |
| 1 May 2024 | $129M | $62.5M – $197M | $129M (0%) | after a round | 25 | growing | B | 0% |
| 1 Jun 2024 | $129M | $63.3M – $197M | $129M (0%) | after a round | 25 | growing | B | 0% |
| 1 Jul 2024 | $129M | $64.1M – $197M | $129M (0%) | after a round | 25 | growing | B | 0% |
| 1 Aug 2024 | $143M | $71.5M – $217M | $143M (0%) | after a round | 39 | growing | B | 0% |
| 1 Sep 2024 | $143M | $66.1M – $217M | $143M (0%) | after a round | 39 | growing | B | 0% |
| 1 Oct 2024 | $143M | $66.3M – $217M | $143M (0%) | after a round | 39 | growing | B | 0% |
| 1 Nov 2024 | $146M | $68.1M – $222M | $146M (0%) | after a round | 43 | growing | B | 0% |
| 1 Dec 2024 | $146M | $68.4M – $222M | $146M (0%) | after a round | 43 | growing | B | 0% |
| 1 Jan 2025 | $146M | $68.7M – $222M | $146M (0%) | after a round | 43 | growing | B | 0% |
| 1 Feb 2025 | $146M | $69.0M – $222M | $146M (0%) | after a round | 43 | growing | B | 0% |
| 14 Feb 2025 | $1.2B | $813M – $2.1B | $1.5B (+30%) | after a round | 43 | growing | B | 0% |
| 1 Mar 2025 | $1.2B | $813M – $2.1B | $1.5B (+29%) | after a round | 43 | growing | B | 0% |
| 1 Apr 2025 | $1.2B | $813M – $2.1B | $1.5B (+26%) | after a round | 43 | growing | B | 0% |
| 1 May 2025 | $1.2B | $813M – $2.1B | $1.5B (+23%) | after a round | 43 | growing | B | 0% |
| 1 Jun 2025 | $1.2B | $813M – $2.1B | $1.5B (+20%) | after a round | 43 | growing | B | 0% |
| 1 Jul 2025 | $1.3B | $813M – $2.1B | $1.5B (+18%) | after a round | 43 | growing | B | 0% |
| 1 Aug 2025 | $1.4B | $897M – $2.3B | $1.7B (+21%) | after a round | 67 | growing | B | 0% |
| 1 Sep 2025 | $1.4B | $908M – $2.4B | $1.7B (+18%) | after a round | 71 | growing | B | 0% |
| 1 Oct 2025 | $1.5B | $908M – $2.4B | $1.7B (+15%) | after a round | 71 | growing | B | 0% |
| 1 Nov 2025 | $1.5B | $919M – $2.4B | $1.7B (+12%) | after a round | 75 | growing | B | 0% |
| 1 Dec 2025 | $1.6B | $919M – $2.4B | $1.7B (+8%) | after a round | 75 | growing | B | 0% |
| 1 Jan 2026 | $1.6B | $919M – $2.4B | $1.7B (+5%) | after a round | 75 | growing | B | 0% |
| 1 Feb 2026 | $1.7B | $919M – $2.4B | $1.7B (+1%) | after a round | 75 | growing | B | 0% |
| 1 Mar 2026 | $1.7B | $932M – $2.4B | $1.7B (0%) | after a round | 79 | growing | B | 0% |
| 1 Apr 2026 | $1.7B | $938M – $2.4B | $1.7B (0%) | after a round | 79 | growing | B | 0% |
| 1 May 2026 | $1.7B | $958M – $2.5B | $1.7B (0%) | after a round | 85 | growing | B | 0% |
| 1 Jun 2026 | $1.7B | $908M – $2.5B | $1.7B (0%) | after a round | 85 | up | B | 0% |
| 1 Jul 2026 | $1.7B | $899M – $2.5B | $1.7B (0%) | after a round | 85 | up | B | 0% |
| 16 Jul 2026 | $2.9B | $2.0B – $5.3B | $3.7B (+30%) | after a round | 93 | growing | B | 0% |
| 1 Aug 2026 | $2.9B | $2.0B – $5.3B | $3.7B (+28%) | after a round | 93 | growing | B | 0% |
| 1 Sep 2026 | $3.0B | $2.0B – $5.3B | $3.7B (+26%) | after a round | 93 | growing | B | 0% |
| 1 Oct 2026 | $3.0B | $2.1B – $5.4B | $3.8B (+25%) | after a round | 101 | growing | B | 0% |
| 24 Oct 2026 | $3.1B | $2.1B – $5.4B | $3.8B (+23%) | after a round | 101 | growing | B | 0% |
Key facts about AdvanCell
- Founded
- 2019
- Headquarters
- Sydney, Australia
- Employees
- about 101 +42% in a year
- Total raised
- $505M
- Funding rounds
- 3
- Last round
- Series D Jul 2026
AdvanCell was founded in 2019 by Andrew Adamovich.
AdvanCell funding history
AdvanCell has 3 funding rounds on record, from Aug 2022 to Jul 2026, $505M in total. None disclosed a valuation.
Series D 15 Jul 2026
Led by Ally Bridge Group, Alpha Wave Global; with Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price, Eventide Asset Management, Velocity Capital, Morningside, Eli Lilly and Company, SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis Capital Management, Tenmile, Brandon Capital, Piper Sandler, Catalio Capital Management, Proto Axiom, Time BioVentures.
Sources: advancell.com.au, advancell.com.au, brandoncapital.vc and 5 more
$315M
Series C 13 Feb 2025
Investors not disclosed.
Sources: startupdaily.net, abingworth.com, globenewswire.com
$178M
$12M
AdvanCell investors
19 investors have backed AdvanCell; Morningside, Ally Bridge Group and Alpha Wave Global led at least one round.
- Morningside lead, 2 rounds
- Alpha Wave Global lead
- Bain Capital Life Sciences
- Eli Lilly and Company
- Eventide Asset Management
- Fidelity Management & Research Company
- Sanofi Ventures
- T. Rowe Price
What AdvanCell does
AdvanCell works in pharmaceutical products, with 9 recorded offerings and customers in healthcare and biotechnology.
AdvanCell Pty Ltd is an Australian radiopharmaceutical company engaged in the development of targeted alpha therapies for cancer treatment. The company conducts research and development in radiopharmaceuticals, clinical research, and regulatory affairs, and manages the supply chain for alpha therapies. AdvanCell also collaborates with biotechnology partners and holds patents related to its technology.
Description from Veridion's company data.
Products and services
- Radiopharmaceutical Development and Manufacturing
- Targeted Alpha Therapy Development
- Oncology Radiopharmaceutical Clinical Development
- Isotope Supply and Distribution
- Radiopharmaceutical Platform Technology Development
- Preclinical Research Services
- Regulatory Affairs Consulting
- Strategic Partnership Development
- Cancer Treatment Technology Advancement
Markets
- Healthcare
- Biotechnology
Technology
- Targeted Alpha Therapy
- Isotope-Based Radiopharmaceutical Supply for Targeted Alpha Therapy
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 325412 Pharmaceutical Preparation Manufacturing 70% match
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers 30% match
Questions about AdvanCell
What is AdvanCell worth?
Valuation $3.1B (range $2.1B to $5.4B), as of 24 Oct 2026.
Has AdvanCell raised money?
AdvanCell has 3 funding rounds on record, from Aug 2022 to Jul 2026, $505M in total. None disclosed a valuation.
Who has invested in AdvanCell?
Morningside, Ally Bridge Group, Alpha Wave Global, Abingworth, Bain Capital Life Sciences and Brandon Capital, and 13 more. Lead investors include Morningside, Ally Bridge Group and Alpha Wave Global.
How many people work at AdvanCell?
About 101, up 42% over the last year. Headcount grew from 7 in Mar 2022 to 101 in Sep 2026.
What does AdvanCell do?
AdvanCell works in pharmaceutical products, with 9 recorded offerings and customers in healthcare and biotechnology. Its main offerings are radiopharmaceutical development and manufacturing, targeted alpha therapy development and oncology radiopharmaceutical clinical development.
When was AdvanCell founded, and where is it based?
AdvanCell was founded in 2019 and is based in Sydney, Australia. It has about 101 employees, up 42% over the last year.